169 related articles for article (PubMed ID: 23618321)
1. Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II.
Lind-Landström T; Varughese RK; Sundstrøm S; Torp SH
Diagn Pathol; 2013 Apr; 8():67. PubMed ID: 23618321
[TBL] [Abstract][Full Text] [Related]
2. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
3. Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors.
Abd El Atti RM; Abou Gabal HH; Osman WM; Saad AS
Diagn Pathol; 2013 Jul; 8():126. PubMed ID: 23902708
[TBL] [Abstract][Full Text] [Related]
4. Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis.
Wharton SB; Chan KK; Anderson JR; Stoeber K; Williams GH
Neuropathol Appl Neurobiol; 2001 Aug; 27(4):305-13. PubMed ID: 11532161
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of histological features in diffuse astrocytomas WHO grade II.
Lind-Landström T; Habberstad AH; Sundstrøm S; Torp SH
Int J Clin Exp Pathol; 2012; 5(2):152-8. PubMed ID: 22400076
[TBL] [Abstract][Full Text] [Related]
6. Grading of diffusely infiltrating astrocytomas by quantitative histopathology, cell proliferation and image cytometric DNA analysis. Comparison of 133 tumours in the context of the WHO 1979 and WHO 1993 grading schemes.
Sallinen PK; Sallinen SL; Helén PT; Rantala IS; Rautiainen E; Helin HJ; Kalimo H; Haapasalo HK
Neuropathol Appl Neurobiol; 2000 Aug; 26(4):319-31. PubMed ID: 10931365
[TBL] [Abstract][Full Text] [Related]
7. Cellular proliferation in pilocytic and diffuse astrocytomas.
Giannini C; Scheithauer BW; Burger PC; Christensen MR; Wollan PC; Sebo TJ; Forsyth PA; Hayostek CJ
J Neuropathol Exp Neurol; 1999 Jan; 58(1):46-53. PubMed ID: 10068313
[TBL] [Abstract][Full Text] [Related]
8. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.
Colman H; Giannini C; Huang L; Gonzalez J; Hess K; Bruner J; Fuller G; Langford L; Pelloski C; Aaron J; Burger P; Aldape K
Am J Surg Pathol; 2006 May; 30(5):657-64. PubMed ID: 16699322
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer.
Yang J; Ramnath N; Moysich KB; Asch HL; Swede H; Alrawi SJ; Huberman J; Geradts J; Brooks JS; Tan D
BMC Cancer; 2006 Aug; 6():203. PubMed ID: 16882345
[TBL] [Abstract][Full Text] [Related]
10. Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance.
Tokuyasu N; Shomori K; Nishihara K; Kawaguchi H; Fujioka S; Yamaga K; Ikeguchi M; Ito H
Gastric Cancer; 2008; 11(1):37-46. PubMed ID: 18373176
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas.
Varughese RK; Skjulsvik AJ; Torp SH
Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203
[TBL] [Abstract][Full Text] [Related]
12. Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis.
Obermann EC; Went P; Zimpfer A; Tzankov A; Wild PJ; Stoehr R; Pileri SA; Dirnhofer S
BMC Cancer; 2005 Dec; 5():162. PubMed ID: 16368013
[TBL] [Abstract][Full Text] [Related]
13. Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas--an assessment of 3 new variables in predicting clinical outcome.
Margraf LR; Gargan L; Butt Y; Raghunathan N; Bowers DC
Neuro Oncol; 2011 Jul; 13(7):767-74. PubMed ID: 21653594
[TBL] [Abstract][Full Text] [Related]
14. MCM2 expression levels predict diagnosis and prognosis in gastric cardiac cancer.
Liu M; Li JS; Tian DP; Huang B; Rosqvist S; Su M
Histol Histopathol; 2013 Apr; 28(4):481-92. PubMed ID: 23329420
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer.
Czyzewska J; Guzińska-Ustymowicz K; Pryczynicz A; Kemona A; Bandurski R
Folia Histochem Cytobiol; 2009; 47(2):289-96. PubMed ID: 19995716
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival.
Hilton DA; Penney M; Evans B; Sanders H; Love S
Am J Surg Pathol; 2002 Apr; 26(4):472-8. PubMed ID: 11914625
[TBL] [Abstract][Full Text] [Related]
17. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas.
Torres-Rendon A; Roy S; Craig GT; Speight PM
Br J Cancer; 2009 Apr; 100(7):1128-34. PubMed ID: 19293805
[TBL] [Abstract][Full Text] [Related]
18. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
19. DNA replication licensing and cell cycle kinetics of normal and neoplastic breast.
Shetty A; Loddo M; Fanshawe T; Prevost AT; Sainsbury R; Williams GH; Stoeber K
Br J Cancer; 2005 Nov; 93(11):1295-300. PubMed ID: 16278669
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder.
Krüger S; Thorns C; Stöcker W; Müller-Kunert E; Böhle A; Feller AC
Eur Urol; 2003 Feb; 43(2):138-45. PubMed ID: 12565771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
